Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $9.20, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $18.50 indicates a 101.1% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $4.81. While the lowest estimate of $11 indicates a 19.6% increase from the current price level, the most optimisti ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Head of Investor Relations Frank Watanabe - President and Chief Executive Officer Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Serge Belanger - Needham Seamus Fernandez - Guggenheim Securities Vikram Purohit - Morgan Stanley Tyler Van Buren - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form10-Q 91361 (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other ...

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update • First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23 • Continued gross-to-net (GTN) improvement with blended GTN across products now in the low 60 percent range • Sustained growth in demand for cream and remarkable uptake of foam launched in January • July 7 ...

Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation dataCrodafos™ CES, used in ZORYVE foam, is suitable for a wide variety of skin and hair typesFindings from this formulation review underscore the suitability of ZORYVE foam for use on all affected areas of the body, and all hair types, in the management of seborrheic dermatitis WESTLAKE VILL ...

Group 1 - Arcutis Biotherapeutics, Inc. will report its first quarter 2024 financial results and provide a business update on May 14, 2024, after U.S. financial markets close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. ET, with a live webcast available on the company's website [1] - An archived replay of the webcast will be accessible on the Arcutis investor website following the conference call [1] Group 2 - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases [2] - The company has two FDA-approved products and a growing portfolio that addresses persistent patient challenges in dermatology [2] - Arcutis' development platform includes a robust pipeline with multiple clinical programs targeting inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [2]

Core Viewpoint - The stock price of Arcutis Biotherapeutics, Inc. (ARQT) has been on a bearish trend, losing 6.5% over the past two weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1]. Technical Analysis - The hammer chart pattern indicates a potential bottom formation, suggesting that selling pressure may be subsiding [1][3]. - A hammer pattern typically forms during a downtrend when the stock opens lower, makes a new low, but then closes near or above the opening price, indicating a shift in control from bears to bulls [2][3]. Fundamental Analysis - There has been a significant upward trend in earnings estimate revisions for ARQT, with the consensus EPS estimate increasing by 6% over the last 30 days, indicating strong agreement among analysts about improved earnings potential [4]. - The Zacks Rank for ARQT is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [5].

Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $10.66, gaining 14.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16.50 indicates a 54.8% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $6.44. While the lowest estimate of $8 indicates a 25% decline from the current price level, the most optimistic a ...

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children treated with roflumilast cream 0.05% achieved a 75% improvement in Eczema Area and Severity Index (EASI-75), a key secondary endpointNew data highlight rapid and significant reduction in itch as early as 24 hours following first application of roflumilast cream 0.05% based on daily Worst Itch Numeric Scale (WI-NRS ...

Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signatureSuggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific pattern SAN DIEGO, Calif., March 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, highlights new research that, for the first time, reveals the gene expression pro ...